United Therapeutics (UTHR) Expected to Announce Quarterly Earnings on Wednesday

United Therapeutics (NASDAQ:UTHR - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Wednesday, April 30th. Analysts expect United Therapeutics to post earnings of $6.29 per share and revenue of $726.82 million for the quarter.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the company posted $4.36 EPS. On average, analysts expect United Therapeutics to post $24 EPS for the current fiscal year and $27 EPS for the next fiscal year.

United Therapeutics Trading Up 3.0 %

UTHR opened at $292.82 on Wednesday. United Therapeutics has a twelve month low of $233.28 and a twelve month high of $417.82. The firm has a market cap of $13.15 billion, a price-to-earnings ratio of 12.86, a PEG ratio of 0.97 and a beta of 0.63. The company has a fifty day simple moving average of $313.33 and a 200 day simple moving average of $347.74.

Analyst Upgrades and Downgrades

UTHR has been the topic of several research reports. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 17th. HC Wainwright reaffirmed a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. JPMorgan Chase & Co. cut their price target on United Therapeutics from $357.00 to $355.00 and set an "overweight" rating on the stock in a report on Monday. Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price on the stock in a research note on Monday. Finally, UBS Group increased their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $395.67.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $353.64, for a total value of $3,536,400.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $911,330.28. This trade represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction that occurred on Thursday, April 17th. The stock was sold at an average price of $283.78, for a total transaction of $3,121,580.00. Following the completion of the transaction, the executive vice president now directly owns 36,781 shares of the company's stock, valued at $10,437,712.18. This represents a 23.02 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 84,500 shares of company stock worth $28,179,150. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.